News - Lundbeck

Filter

Current filters:

Lundbeck

Popular Filters

46 to 70 of 92 results

FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia

01-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received…

Abilify MaintenaAlkermesLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Lundbeck buoyed as EU gives green light to alcohol addiction drug

01-03-2013

Danish pharma company Lundbeck (LUND: DC) is celebrating after winning European Union approval for Selincro…

EuropeLundbeckNeurologicalPharmaceuticalRegulationSelincro

Lundbeck sales of new products up more than 70%, but earnings miss expectations

06-02-2013

Denmark-based CNS drug specialist Lundbeck (LUND: DC) saw its shares drift 1.2% lower to 87.55 Danish…

FinancialLundbeckPharmaceutical

European Commission enforcement action in pharmaceutical sector following sector inquiry

31-01-2013

Following its competition inquiry into the pharmaceutical sector of 2008/2009, the European Commission…

DuragesicEuropeGenericsJohnson & JohnsonLundbeckMarkets & MarketingPatentsPharmaceuticalServier

Recordati buys US portfolio of drugs from Lundbeck

17-12-2012

Italian drugmaker Recordati *RC: MI) has signed an agreement for the acquisition of all rights concerning…

LundbeckMergers & AcquisitionsNorth AmericaPharmaceuticalRare diseasesRecordati

European Alzheimer's drug market to grow to $4.78 billion by 2019, says F&S

25-11-2012

The patent expiry of all four existing European Medicines Agency-approved drugs for Alzheimer's disease…

AriceptEbixaEisaiEuropeExelon PatchLundbeckMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalResearch

Lundbeck beats expectations, despite Lexapro slump

07-11-2012

Danish CNS drug specialist Lundbeck (LUND: DC) this morning reported third-quarter 2012 financial results,…

FinancialLundbeckPharmaceutical

Lundbeck in neurodegeneration collaboration with ImaginAb

09-10-2012

ImaginAb Inc, a clinical-stage US company developing in vivo molecular imaging agents based on antibody…

ImaginAbLicensingLundbeckNeurologicalPharmaceuticalResearch

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine

21-09-2012

US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

Resubmission of aripiprazole NDA accepted; AstraZeneca bond issue

12-09-2012

Danish CNS-focused drugmaker Lundbeck (LUND: DC) and Japanese partner Otsuka Pharmaceutical (TYO: 4668)…

aripiprazole depotAstraZenecaFinancialLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal

07-09-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Lundbeck gets marketing OK for Treanda in Canada

29-08-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) says that medicines regulator Health Canada has approved…

LundbeckNorth AmericaOncologyPharmaceuticalRegulationTreanda

New products helping overcome generic competition for Lexapro, says Lundbeck

08-08-2012

Danish CNS drugmaker Lundbeck reported first-half 2012 sales of 7.34 billion Danish kroner ($1.22 billion),…

FinancialLicensingLu AE58054LundbeckPharmaceutical

Patient share of Teva/Lundbeck's Azilect for Parkinson's continues to grow

01-08-2012

Through examination of US patient-level claims data, that patient share of Azilect (rasagiline) - from…

AzilectLundbeckMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

EU Commission moves forward on anti-trust issues with Lundbeck and others

26-07-2012

The European Commission yesterday advised Danish CNS drug specialist Lundbeck (LUN: CO) of its objections…

citalopramEuropeGenericsLegalLundbeckMarkets & MarketingNeurologicalPharmaceutical

Biotie assets available for partnering; update on tozadenant

08-07-2012

Finland-based biotech firm Biotie Therapies' (OMX: BTH1V) retention of SYN120 rights after Roche decided…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckNeurologicalResearchSelincroSYN120tozadenantUCB

Lundbeck restructures, with 600 job cuts anticipated

17-06-2012

Denmark-based CNS specialist Lundbeck (LUN: CO) last week announced plans to restructure its commercial…

FinancialLundbeckManagementNeurologicalPharmaceutical

Alzheimer's drug candidate Lu AE58054 meets primary endpoint, says Lundbeck

29-05-2012

Danish CNS drug specialist Lundbeck (LUND: DC) announced this morning that its investigational compound…

Lu AE58054LundbeckNeurologicalPharmaceuticalResearch

46 to 70 of 92 results

Back to top